Catalyst Pharmaceuticals (FRA:CN2) E10: €0.49 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CN2 Catalyst Pharmaceuticals Inc FRA:CN2
93 GF Score
Price €27.30
GF Value €21.47
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Catalyst Pharmaceuticals E10?

Catalyst Pharmaceuticals FRA:CN2 93 E10 is €0.49 as of Mar. 2026. GuruFocus rates FRA:CN2 with a GF Score™ of 93/100 and a GF Value™ of €21.47 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Catalyst Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was €0.432. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.49 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Catalyst Pharmaceuticals's average E10 Growth Rate was 63.90% per year. During the past 3 years, the average E10 Growth Rate was 135.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Catalyst Pharmaceuticals was 135.10% per year. The lowest was 4.20% per year. And the median was 15.10% per year.

As of today (2026-07-22), Catalyst Pharmaceuticals's current stock price is €27.30. Catalyst Pharmaceuticals's E10 for the quarter that ended in Mar. 2026 was €0.49. Catalyst Pharmaceuticals's Shiller PE Ratio of today is 55.71.

During the past 13 years, the highest Shiller PE Ratio of Catalyst Pharmaceuticals was 950.50. The lowest was 41.85. And the median was 88.04.


Catalyst Pharmaceuticals  (FRA:CN2) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Catalyst Pharmaceuticals's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=27.30/0.49
=55.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Catalyst Pharmaceuticals was 950.50. The lowest was 41.85. And the median was 88.04.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Catalyst Pharmaceuticals E10 Related Terms


Catalyst Pharmaceuticals E10 Historical Data

* Premium members only.

The historical data trend for Catalyst Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catalyst Pharmaceuticals E10 Chart

Catalyst Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 0.04 0.13 0.29 0.45

Catalyst Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 0.36 0.39 0.45 0.49

FRA:CN2 vs CRNX, NAMS, RCUS: E10 Comparison

For the Biotechnology subindustry, Catalyst Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalyst Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Catalyst Pharmaceuticals's Shiller PE Ratio falls into.


FRA:CN2
93GF Score
Catalyst Pharmaceuticals Inc FRA:CN2
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Catalyst Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Catalyst Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.432/330.2130*330.2130
=0.432

Current CPI (Mar. 2026) = 330.2130.

Catalyst Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201606 -0.053 241.018 -0.073
201609 -0.045 241.428 -0.062
201612 -0.047 241.432 -0.064
201703 -0.056 243.801 -0.076
201706 -0.045 244.955 -0.061
201709 -0.042 246.819 -0.056
201712 -0.051 246.524 -0.068
201803 -0.049 249.554 -0.065
201806 -0.051 251.989 -0.067
201809 -0.069 252.439 -0.090
201812 -0.123 251.233 -0.162
201903 -0.009 254.202 -0.012
201906 0.089 256.143 0.115
201909 0.118 256.759 0.152
201912 0.063 256.974 0.081
202003 0.090 258.115 0.115
202006 0.080 257.797 0.102
202009 0.348 260.280 0.442
202012 0.090 260.474 0.114
202103 0.059 264.877 0.074
202106 0.091 271.696 0.111
202109 0.085 274.310 0.102
202112 0.080 278.802 0.095
202203 0.109 287.504 0.125
202206 0.189 296.311 0.211
202209 0.202 296.808 0.225
202212 0.208 296.797 0.231
202303 0.243 301.836 0.266
202306 0.305 305.109 0.330
202309 -0.272 307.789 -0.292
202312 0.284 306.746 0.306
202403 0.175 312.332 0.185
202406 0.307 314.175 0.323
202409 0.315 315.301 0.330
202412 0.420 315.605 0.439
202503 0.416 319.799 0.430
202506 0.355 322.561 0.363
202509 0.358 324.800 0.364
202512 0.350 324.054 0.357
202603 0.432 330.213 0.432

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €0.49 mean?
Catalyst Pharmaceuticals (FRA:CN2) has a E10 of €0.49 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Catalyst Pharmaceuticals and its competitors.
Is Catalyst Pharmaceuticals' E10 too high?
Catalyst Pharmaceuticals' current E10 is €0.49. Overall, Catalyst Pharmaceuticals has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Catalyst Pharmaceuticals' E10 compare to CRNX and NAMS?
Catalyst Pharmaceuticals' E10 of €0.49 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Catalyst Pharmaceuticals and its competitors. Catalyst Pharmaceuticals's current E10 is €0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catalyst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals (FRA:CN2) is currently considered Modestly Overvalued. The stock's GF Value™ is €21.47, compared to a current price of €27.30 — trading 27.2% above its estimated fair value. The current E10 is €0.49. Catalyst Pharmaceuticals' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Catalyst Pharmaceuticals (FRA:CN2), the current E10 is €0.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Catalyst Pharmaceuticals (FRA:CN2) Overvalued in 2026?

Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued. The current stock price of €27.30 is trading 27.2% above its estimated GF Value™ of €21.47. GuruFocus considers Catalyst Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for FRA:CN2:

  • E10: €0.49
  • GF Value™: €21.47 vs. price of €27.30 (27.2% above fair value)
  • GF Score™: 93/100 with 6 warning signs

No single metric tells the full story. See the FRA:CN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Catalyst Pharmaceuticals Business Description

Other Exchanges CPRX:USACN2:Germany
Address 355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
93GF Score

Get the complete analysis for FRA:CN2

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€27.30
Price
€21.47
GF Value